Only members of the media with a credentialed press badge will have access to the Press Room (on-site and online).

Public relations and industry representatives will not have access to the Press Room. They may, however, call upon the CRF^® Press Staff to help them facilitate media requests.

Only preapproved media materials may be made available in the press room. Press releases must mention Transcatheter Cardiovascular Therapeutics^® (TCT^®) and the Cardiovascular Research Foundation^® (CRF^®) in order to have them posted in the press room (see News Release Policy).

Exhibiting companies are permitted to hold media events during TCT^® 2025, provided that they relate directly to research presented at TCT^® and do not conflict with official TCT^® press activities or policies.

Companies planning media events during TCT^® 2025 are required to obtain written approval from CRF^® in advance of the meeting by contacting CRF’s Associate Director of External Relations, Judy Romero, at [email protected].

Exhibiting companies are asked to hold press events or analyst briefings during dates and times that do not conflict with official TCT^® 2025 press activities. A final press conference schedule will be available from the CRF^® Press Office a few weeks in advance of TCT^® 2025.

Media, investigators, organizations issuing press releases, and others with access to research accepted for presentation during TCT^® 2025 are required to abide by the embargo policies governing CRF^® meetings.

The Cardiovascular Research Foundation^® embargoes information presented as a late-breaking clinical trial, late-breaking clinical science, or featured clinical research. Coverage of these studies is strictly prohibited until the start time of each trial’s official presentation as listed in the TCT^® 2025 Program on the official TCT^® website. No journalist, exhibitor, or university (or affiliated organization or company) may disseminate information until the trial’s official presentation time. All embargo times are listed in Pacific Daylight Time (PDT). There is no official embargo for research presented as an abstract, challenging case, or during an innovation session. However, to maximize the impact of your presentation, we recommend that no data be shared until the start of the TCT^® 2025 meeting (Saturday, October 25, 2025 at 7:00 AM PDT) and ideally not before your formal presentation.

Organizations presenting research at TCT^® 2025 may not engage in embargoed media outreach, conduct embargoed interviews, or share embargoed presentation materials without prior approval from the CRF^® Press Office.

For questions regarding the embargo policy, please email [email protected].

Industry may display news releases in the press area provided they adhere to the following policy:

• Only companies exhibiting or presenting research at TCT^® 2025 may display materials in the press area. All press materials must relate directly to the meeting. CRF^® reserves the right to prohibit and/or discard materials deemed scientifically misleading, ethically questionable, or irrelevant to the meeting.
• All news releases must abide by CRF^®’s embargo policy and will not be permitted to be displayed or posted in the press area prior to the embargo date and time.
• Curtain-opener press releases previewing science to be presented at TCT^® 2025 may be issued but must not disclose any embargoed information.
• Releases must reference the Cardiovascular Research Foundation^®’s annual Transcatheter Cardiovascular Therapeutics^® (TCT^®) scientific symposium in the body of the release, preferably in the first paragraph. Suggested language is provided below.
• All press releases referencing TCT^® 2025 and related events or presentations must receive approval from the CRF^® Press Office prior to distribution. A copy or draft of the press release must be submitted in advance for review and approval. To obtain approval, please email the press release to the contact below. All submissions will be treated with strict confidentiality.
• Releases must not imply that CRF^® endorses any product or service.
• Releases must not be scientifically misleading or ethically questionable.

CRF^® Press Office Contact
Judy Romero
646.434.4608
[email protected]

Suggested Language (Included in First Paragraph)

… presented at Transcatheter Cardiovascular Therapeutics^® (TCT^®), the annual scientific symposium of the Cardiovascular Research Foundation^® (CRF^®).

The TCT^® scientific symposium routinely attracts more than 100 medical and business reporters from a wide range of disciplines, including national wire services, newspapers, U.S. and international trade publications (cardio/pharma/medical/device), and popular news and health information websites.

The Cardiovascular Research Foundation^® does not provide a media or attendee registration list of any type.